OncoMatch/Clinical Trials/NCT06935162
Teclistamab in Previously Treated AL Amyloidosis
Is NCT06935162 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Teclistamab (Tec) for al amyloidosis.
Treatment: Teclistamab (Tec) — This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: (daratumumab, bortezomib)
Patients must have received at least one line of treatment, including daratumumab and bortezomib; Relapse from previous treatment, or less than partial response after two cycles of treatment/less than very good partial response after three cycles of treatment
Cannot have received: anti-BCMA targeted therapy
Previous anti-BCMA targeted therapy
Lab requirements
Blood counts
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L
Kidney function
eGFR < 20 mL/min, or receiving renal replacement therapy
Liver function
ALT or AST > 5 × ULN, total bilirubin > 2 × ULN
Cardiac function
grade 2 Mobitz II or grade 3 atrioventricular block (except for those with implanted pacemaker); sustained or recurrent nonsustained ventricular tachycardia
Neutrophil <1×10E9/L, hemoglobin < 8g/dL, or platelet < 75×10E9/L. Severely compromised hepatic or renal function: ALT or AST > 5 × ULN, total bilirubin > 2 × ULN, eGFR < 20 mL/min, or receiving renal replacement therapy. Grade 2 Mobitz II or grade 3 atrioventricular block (except for those with implanted pacemaker); sustained or recurrent nonsustained ventricular tachycardia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06935162 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-BCMA targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages